This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Peutz-Jeghers Syndrome (STK11) and pancreatic cancer

Authoring team

Peutz-Jeghers Syndrome (STK11) and pancreatic cancer

  • Peutz-Jeghers syndrome is an autosomal dominant syndrome characterized by melanocytic macules on the lips and buccal mucosa, and hamartomatous polyps of the gastrointestinal tract (1,2,3)
    • Peutz-Jeghers syndrome (PJS) is caused by germline mutations in the STK11 gene (3)
    • in addition to gastrointestinal and breast cancer, patients with the Peutz-Jeghers syndrome have a very high risk of developing pancreatic cancer
    • reported that 80% of STK11 mutation carriers develop cancer by the age of 60 years (1)
    • STK11 gene is located on 19p13.3 (2)
    • reported that patients with the syndrome have a remarkable 132-fold increased risk of developing pancreatic cancer (1)
    • cumulative risk of developing any gastrointestinal cancer is 38-66% at age 70 (3)
    • cumulative risk of developing pancreatic cancer at age 70 in PJS patients is 11-55% (3)


Reference:

  • Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic cancer. Adv Surg. 2010;44:293-311. doi:10.1016/j.yasu.2010.05.011
  • Petersen GM. Familial pancreatic cancer. Semin Oncol. 2016;43(5):548-553. doi:10.1053/j.seminoncol.2016.09.002
  • Chen F, Roberts NJ, Klein AP. Inherited pancreatic cancer. Chin Clin Oncol. 2017;6(6):58. doi:10.21037/cco.2017.12.04

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.